BMO Capital analyst Alex Arfaei lowered his price target on Eli Lilly to $130, saying the stock has underperformed along with its peers, and the news around its Tanezumab announced last week was "obviously negative". The analyst is keeping his Outperform rating however and believes that risk-reward on Eli Lilly is still "attractive" based on his "higher forecasts for Trulicity, Taltz, and Jardiance", as well as expectations around "improved margins". Arfaei adds that the company's upcoming REWIND data at the American Diabetes Association summit could be the "next major catalyst" for Eli Lilly shares.